View Financial HealthKDA Group 배당 및 자사주 매입배당 기준 점검 0/6KDA Group 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-11.6%자사주 매입 수익률총 주주 수익률-11.6%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 07+ 1 more updateKDA Group Inc. Announces Settlement of Judicial ClaimsKDA Group Inc. announced that it has settled a dispute with a former executive officer of the Corporation who claimed from the Corporation a total of $808,191 plus interest and expenses, as well as the issuance of 1,000,000 shares of the capital stock of the Corporation pursuant to his employment contract terminated by the Corporation in July 2022. The Corporation, for its part, was claiming a total of $474,200 plus interest and costs from this former executive. The parties settled this dispute, and the Court ratified the settlement on May 4, 2026. Pursuant to the Settlement, the Corporation has agreed to pay the former executive compensation on May 31, 2026, in the amount of $215,000 payable as follows: (i) the payment of $190,000 and (ii) the issuance of 250,000 common shares at a value of $0.10 per share. The Corporation must obtain the approval of the TSX Venture Exchange for the issuance of these shares, and they will be subject to a hold period of four months and one day from the date of issuance, in accordance with applicable securities regulations. The Corporation also announces that it has settled, on March 23, 2026, another dispute involving a former executive who claimed $760,000 from the Corporation under the terms of his employment contract terminated by the Corporation in September 2021. Pursuant to the settlement, the Corporation has agreed to pay the former executive an amount of $215,000 payable on or before April 24, 2026.공시 • Mar 05KDA Group Inc., Annual General Meeting, Apr 29, 2026KDA Group Inc., Annual General Meeting, Apr 29, 2026. Location: quebec, quebec city Canada공시 • Mar 03+ 1 more updateKDA Group Inc. Announces Executive and Board ChangesKDA Group Inc. announced the appointment of Mr. Jean-Marc Léveillé as President and Chairman of the Board of Directors of KDA effective February 27, 2026. The Corporation announced the departure of its former President, Marc Lemieux, who will remain a director of the Company until the next shareholders' meeting. Mr. Léveillé has been a director of KDA since February 20, 2025, and has the experience and leadership necessary to ensure the Corporation's transition from the development phase of its healthcare technology products to the large-scale commercialization phase. Jean-Marc Léveillé is a CRIA Fellow with a background in organizational transformation, modern governance, and strategic talent management in highly specialized sectors. A former member of senior management and head of human resources at Marine Industrie (Vickers division) in the naval sector and at Héroux-Devtek in the aerospace sector, he contributed to the reorganization and transformation of these companies to world-class standards, where technical and specialized skills were at the heart of business strategies. As president of Élitis Pharma, Dotemtex Executive Search, Dotemtex Transition, and Prosygma, Mr. Léveillé has spent more than 20 years assisting public, private, and parapublic organizations in modernizing their governance, optimizing their performance, and managing strategic succession. He has also directed the Quebec Philharmonic Orchestra.공시 • May 30KDA Group Inc. announced that it has received CAD 2.2 million in fundingKDA Group Inc announced a private placement to issue 8,800,000 units at a price of CAD 0.25 per Unit for total gross proceeds of CAD 2,200,000 on May 29, 2025. Each Unit consists of one Class A Share and one Common share purchase warrant. Each Warrant entitles the holder to purchase one additional Common share of the Corporation at an exercise price of CAD 0.35 per Common share for a period of 24 months ending May 29, 2027. All securities issued pursuant to the Private Placement are subject to a mandatory four-month and one day hold period expiring on September 30, 2025 in accordance with applicable securities regulations. The transaction included participation from accredited investors. The Private Placement was carried out pursuant to prospectus exemptions of applicable securities laws and is subject to final acceptance by the TSX Venture Exchange. Insider, Marc Lemieux purchased 80,000 Units for a total consideration of CAD 20,000. Marc Lemieux is hereinafter referred to as the “Insider”. No finder’s fee nor commission are payable in connection with the Private Placement.공시 • May 22KDA Group Inc. Receives DSQ Certification for Adherize+ PlatformKDA Group Inc. announced that its Adherize+ platform, designed to optimize patient follow-up and care coordination, has officially received certification from Dossier Sante Quebec ("DSQ"). This authorization marks a major step toward full production deployment. At the core of Adherize+ is Medherize, a high-impact specialized module developed to support interdisciplinary follow-up for patients undergoing targeted cancer therapies. Leveraging structured, real-time data exchange through granular integration, a first in Quebec, Medherize brings significant value to healthcare operations and outcomes, positioning it as a key strategic asset within the Adherize+ ecosystem for the entire Quebec population. With this certification secured, the pilot project at Hopital Saint-Sacrement in Quebec City is set to begin, marking the start of a phased rollout to other healthcare institutions across the province. As more specialty therapies are delivered orally and managed outside of hospitals by community pharmacies, the need for robust digital tools like Medherize are becoming essential for physicians, pharmacists, and nursing staff. These high-cost treatments are often associated with significant adverse effects and adherence challenges. Ensuring appropriate monitoring can directly impact patient survival and reduce systemic risks. Medherize is designed to meet this growing need, improving continuity of care for patients whose lives depend on strict therapeutic management.공시 • Apr 16KDA Group Inc. Reaches Final Certification Phase for Medherize with Dossier Sante QuebecKDA Group Inc. announced that it has reached the final phase in the certification process for its Medherize platform's integration with the Dossier Sante Quebec ("DSQ"). Following the successful completion of the initial certification phase announced on December 3, 2024, all three required development phases for the module have now been completed. On April 7, 2025, the Direction des produces de prestations de services du DSQ, through its Integration and Certification Support Team, confirmed that the final self-assessment phase was successfully passed. The final audit is scheduled for April 22-24, 2025, marking the last technical validation before full integration. The initial deployment of Medherize is planned for May 5, 2025, at the St-Sacrement Hospital Center in Quebec City, followed by a progressive rollout across other healthcare institutions in the province. KDA is now the first technology provider in Quebec to successfully certify for DSQ integration using the granular data mode--a major advancement in the transmission of clinical information. Unlike laboratory results delivered in PDF format, which are often static and difficult to process, the granular mode enables structured, interoperable, and seamlessly integrable data within clinical systems. This model provides substantial gains in efficiency, safety, quality of care, as well as reductions in delays and human error.공시 • Feb 25KDA Group Inc. Approves the Appointment of Jean-Marc Léveillé as Members of the Audit CommitteeKDA Group Inc. at its annual general meeting of shareholders held on February 20, 2025 approved the appointment of Jean-Marc Léveillé as members of the Corporation's audit committee.공시 • Dec 24KDA Group Inc., Annual General Meeting, Feb 20, 2025KDA Group Inc., Annual General Meeting, Feb 20, 2025. Location: quebec, quebec Canada공시 • Jun 13KDA Group Inc. Announces the Development of Medherize, A New Clinical Management Solution for Specialized Medics for Breast CancerKDA Group Inc. announced the launch of Medherize, its revolutionary new platform dedicated to the clinical management of patients requiring specialized medications. This pioneering project particularly focuses on CDK 4/6 inhibitors used in the treatment of breast cancer, with the objective of ensuring optimal and personalized patient follow-up. Medherize marks the first collaboration among specialist doctors, pharmacists and patients to offer integrated and coordinated care. KDA's new clinical management solution is designed to address the complex challenges associated with the administration of CDK 4/6 inhibitors, essential medications in the treatment of certain types of breast cancer. This innovative technology offers an integrated platform enabling healthcare professionals to accurately monitor patient treatments, track side effects and adjust doses in real-time while ensuring seamless communication between patients and care providers. Key Features of Medherize: Personalized Patient Follow-Up: An intuitive user interface allowing doctors to personalize and track treatment plans for each patient, ensuring better adherence to prescribed therapies. Real-Time Monitoring: Integration of monitoring devices that collect real-time data on patients' health status, enabling rapid intervention when needed. Side Effect Management: A proactive notification system to monitor and manage potential side effects of CDK 4/6 inhibitor. Optimized Communication: A secure communication platform facilitating exchanges between patients, doctors and pharmacists, thereby enhancing care coordination. Analysis and Reporting. Advanced analytical tools to generate detailed reports on treatment effectiveness, supporting evidence-based clinical decision-making. This pilot project, the first of its kind, will be deployed in the Corporation's partner clinics and hospitals in the coming months, with ambitions to expand internationally. KDA remains committed to investing in innovation and closely collaborating with healthcare professionals to continue developing cutting-edge solutions that meet the evolving needs of the healthcare sector. Artificial intelligence and new technologies could reduce healthcare spending by $200 to $360 billion.공시 • Mar 16KDA Group Inc., Annual General Meeting, May 16, 2024KDA Group Inc., Annual General Meeting, May 16, 2024.공시 • Dec 09KDA Group Inc. announced that it has received CAD 1.125 million in fundingKDA Group Inc. announced a private placement to issue 11,250,000 units at an issue price of CAD 0.10 per unit for the gross proceeds of CAD 1.250,000 on December 8, 2023. Each Unit consists of one Class A Share and one Common share purchase warrant. Each Warrant entitles the holder to purchase one additional Common share of the Corporation at an exercise price of CAD 0.15 per Common share for a period of 24 months ending December 8, 2025. The transaction included participation from accredited investors. All securities issued pursuant to the Private Placement are subject to a mandatory four-month and one day hold period expiring on April 9, 2024 in accordance with applicable securities regulations. No finder’s fee nor commission are payable in connection with the Private Placement. The Private Placement was carried out pursuant to prospectus exemptions of applicable securities laws and is subject to final acceptance by the TSX Venture Exchange.공시 • Jun 29KDA Group Inc. (TSXV:KDA) entered into an agreement to acquire right, title and interest in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million.KDA Group Inc. (TSXV:KDA) entered into an agreement to acquire right, title and interest in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million on June 27, 2023. The consideration will be paid through the issuance of 10,000,000 Class A shares in the share capital of KDA Group. ZoomMed Board of Directors has unanimously approved an agreement for the sale. The transaction will be completed following the satisfaction or waiver of all closing conditions provided for in the asset purchase agreement, including the approval by the shareholders of the ZoomMed and obtaining the approvals from applicable regulatory authorities.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 KDAG.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: KDAG.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장KDA Group 배당 수익률 vs 시장KDAG.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (KDAG.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Healthcare Services)1.3%분석가 예측 (KDAG.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 KDAG.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 KDAG.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 KDAG.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: KDAG.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/31 19:56종가2026/05/07 00:00수익2026/01/31연간 수익2025/07/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스KDA Group Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 07+ 1 more updateKDA Group Inc. Announces Settlement of Judicial ClaimsKDA Group Inc. announced that it has settled a dispute with a former executive officer of the Corporation who claimed from the Corporation a total of $808,191 plus interest and expenses, as well as the issuance of 1,000,000 shares of the capital stock of the Corporation pursuant to his employment contract terminated by the Corporation in July 2022. The Corporation, for its part, was claiming a total of $474,200 plus interest and costs from this former executive. The parties settled this dispute, and the Court ratified the settlement on May 4, 2026. Pursuant to the Settlement, the Corporation has agreed to pay the former executive compensation on May 31, 2026, in the amount of $215,000 payable as follows: (i) the payment of $190,000 and (ii) the issuance of 250,000 common shares at a value of $0.10 per share. The Corporation must obtain the approval of the TSX Venture Exchange for the issuance of these shares, and they will be subject to a hold period of four months and one day from the date of issuance, in accordance with applicable securities regulations. The Corporation also announces that it has settled, on March 23, 2026, another dispute involving a former executive who claimed $760,000 from the Corporation under the terms of his employment contract terminated by the Corporation in September 2021. Pursuant to the settlement, the Corporation has agreed to pay the former executive an amount of $215,000 payable on or before April 24, 2026.
공시 • Mar 05KDA Group Inc., Annual General Meeting, Apr 29, 2026KDA Group Inc., Annual General Meeting, Apr 29, 2026. Location: quebec, quebec city Canada
공시 • Mar 03+ 1 more updateKDA Group Inc. Announces Executive and Board ChangesKDA Group Inc. announced the appointment of Mr. Jean-Marc Léveillé as President and Chairman of the Board of Directors of KDA effective February 27, 2026. The Corporation announced the departure of its former President, Marc Lemieux, who will remain a director of the Company until the next shareholders' meeting. Mr. Léveillé has been a director of KDA since February 20, 2025, and has the experience and leadership necessary to ensure the Corporation's transition from the development phase of its healthcare technology products to the large-scale commercialization phase. Jean-Marc Léveillé is a CRIA Fellow with a background in organizational transformation, modern governance, and strategic talent management in highly specialized sectors. A former member of senior management and head of human resources at Marine Industrie (Vickers division) in the naval sector and at Héroux-Devtek in the aerospace sector, he contributed to the reorganization and transformation of these companies to world-class standards, where technical and specialized skills were at the heart of business strategies. As president of Élitis Pharma, Dotemtex Executive Search, Dotemtex Transition, and Prosygma, Mr. Léveillé has spent more than 20 years assisting public, private, and parapublic organizations in modernizing their governance, optimizing their performance, and managing strategic succession. He has also directed the Quebec Philharmonic Orchestra.
공시 • May 30KDA Group Inc. announced that it has received CAD 2.2 million in fundingKDA Group Inc announced a private placement to issue 8,800,000 units at a price of CAD 0.25 per Unit for total gross proceeds of CAD 2,200,000 on May 29, 2025. Each Unit consists of one Class A Share and one Common share purchase warrant. Each Warrant entitles the holder to purchase one additional Common share of the Corporation at an exercise price of CAD 0.35 per Common share for a period of 24 months ending May 29, 2027. All securities issued pursuant to the Private Placement are subject to a mandatory four-month and one day hold period expiring on September 30, 2025 in accordance with applicable securities regulations. The transaction included participation from accredited investors. The Private Placement was carried out pursuant to prospectus exemptions of applicable securities laws and is subject to final acceptance by the TSX Venture Exchange. Insider, Marc Lemieux purchased 80,000 Units for a total consideration of CAD 20,000. Marc Lemieux is hereinafter referred to as the “Insider”. No finder’s fee nor commission are payable in connection with the Private Placement.
공시 • May 22KDA Group Inc. Receives DSQ Certification for Adherize+ PlatformKDA Group Inc. announced that its Adherize+ platform, designed to optimize patient follow-up and care coordination, has officially received certification from Dossier Sante Quebec ("DSQ"). This authorization marks a major step toward full production deployment. At the core of Adherize+ is Medherize, a high-impact specialized module developed to support interdisciplinary follow-up for patients undergoing targeted cancer therapies. Leveraging structured, real-time data exchange through granular integration, a first in Quebec, Medherize brings significant value to healthcare operations and outcomes, positioning it as a key strategic asset within the Adherize+ ecosystem for the entire Quebec population. With this certification secured, the pilot project at Hopital Saint-Sacrement in Quebec City is set to begin, marking the start of a phased rollout to other healthcare institutions across the province. As more specialty therapies are delivered orally and managed outside of hospitals by community pharmacies, the need for robust digital tools like Medherize are becoming essential for physicians, pharmacists, and nursing staff. These high-cost treatments are often associated with significant adverse effects and adherence challenges. Ensuring appropriate monitoring can directly impact patient survival and reduce systemic risks. Medherize is designed to meet this growing need, improving continuity of care for patients whose lives depend on strict therapeutic management.
공시 • Apr 16KDA Group Inc. Reaches Final Certification Phase for Medherize with Dossier Sante QuebecKDA Group Inc. announced that it has reached the final phase in the certification process for its Medherize platform's integration with the Dossier Sante Quebec ("DSQ"). Following the successful completion of the initial certification phase announced on December 3, 2024, all three required development phases for the module have now been completed. On April 7, 2025, the Direction des produces de prestations de services du DSQ, through its Integration and Certification Support Team, confirmed that the final self-assessment phase was successfully passed. The final audit is scheduled for April 22-24, 2025, marking the last technical validation before full integration. The initial deployment of Medherize is planned for May 5, 2025, at the St-Sacrement Hospital Center in Quebec City, followed by a progressive rollout across other healthcare institutions in the province. KDA is now the first technology provider in Quebec to successfully certify for DSQ integration using the granular data mode--a major advancement in the transmission of clinical information. Unlike laboratory results delivered in PDF format, which are often static and difficult to process, the granular mode enables structured, interoperable, and seamlessly integrable data within clinical systems. This model provides substantial gains in efficiency, safety, quality of care, as well as reductions in delays and human error.
공시 • Feb 25KDA Group Inc. Approves the Appointment of Jean-Marc Léveillé as Members of the Audit CommitteeKDA Group Inc. at its annual general meeting of shareholders held on February 20, 2025 approved the appointment of Jean-Marc Léveillé as members of the Corporation's audit committee.
공시 • Dec 24KDA Group Inc., Annual General Meeting, Feb 20, 2025KDA Group Inc., Annual General Meeting, Feb 20, 2025. Location: quebec, quebec Canada
공시 • Jun 13KDA Group Inc. Announces the Development of Medherize, A New Clinical Management Solution for Specialized Medics for Breast CancerKDA Group Inc. announced the launch of Medherize, its revolutionary new platform dedicated to the clinical management of patients requiring specialized medications. This pioneering project particularly focuses on CDK 4/6 inhibitors used in the treatment of breast cancer, with the objective of ensuring optimal and personalized patient follow-up. Medherize marks the first collaboration among specialist doctors, pharmacists and patients to offer integrated and coordinated care. KDA's new clinical management solution is designed to address the complex challenges associated with the administration of CDK 4/6 inhibitors, essential medications in the treatment of certain types of breast cancer. This innovative technology offers an integrated platform enabling healthcare professionals to accurately monitor patient treatments, track side effects and adjust doses in real-time while ensuring seamless communication between patients and care providers. Key Features of Medherize: Personalized Patient Follow-Up: An intuitive user interface allowing doctors to personalize and track treatment plans for each patient, ensuring better adherence to prescribed therapies. Real-Time Monitoring: Integration of monitoring devices that collect real-time data on patients' health status, enabling rapid intervention when needed. Side Effect Management: A proactive notification system to monitor and manage potential side effects of CDK 4/6 inhibitor. Optimized Communication: A secure communication platform facilitating exchanges between patients, doctors and pharmacists, thereby enhancing care coordination. Analysis and Reporting. Advanced analytical tools to generate detailed reports on treatment effectiveness, supporting evidence-based clinical decision-making. This pilot project, the first of its kind, will be deployed in the Corporation's partner clinics and hospitals in the coming months, with ambitions to expand internationally. KDA remains committed to investing in innovation and closely collaborating with healthcare professionals to continue developing cutting-edge solutions that meet the evolving needs of the healthcare sector. Artificial intelligence and new technologies could reduce healthcare spending by $200 to $360 billion.
공시 • Mar 16KDA Group Inc., Annual General Meeting, May 16, 2024KDA Group Inc., Annual General Meeting, May 16, 2024.
공시 • Dec 09KDA Group Inc. announced that it has received CAD 1.125 million in fundingKDA Group Inc. announced a private placement to issue 11,250,000 units at an issue price of CAD 0.10 per unit for the gross proceeds of CAD 1.250,000 on December 8, 2023. Each Unit consists of one Class A Share and one Common share purchase warrant. Each Warrant entitles the holder to purchase one additional Common share of the Corporation at an exercise price of CAD 0.15 per Common share for a period of 24 months ending December 8, 2025. The transaction included participation from accredited investors. All securities issued pursuant to the Private Placement are subject to a mandatory four-month and one day hold period expiring on April 9, 2024 in accordance with applicable securities regulations. No finder’s fee nor commission are payable in connection with the Private Placement. The Private Placement was carried out pursuant to prospectus exemptions of applicable securities laws and is subject to final acceptance by the TSX Venture Exchange.
공시 • Jun 29KDA Group Inc. (TSXV:KDA) entered into an agreement to acquire right, title and interest in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million.KDA Group Inc. (TSXV:KDA) entered into an agreement to acquire right, title and interest in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million on June 27, 2023. The consideration will be paid through the issuance of 10,000,000 Class A shares in the share capital of KDA Group. ZoomMed Board of Directors has unanimously approved an agreement for the sale. The transaction will be completed following the satisfaction or waiver of all closing conditions provided for in the asset purchase agreement, including the approval by the shareholders of the ZoomMed and obtaining the approvals from applicable regulatory authorities.